Organic Active Ingredients TRIZ Cases

Five-coordinate nickel centers catalyze superoxide dismutation to suppress abnormal protein aggregation and protect dopaminergic cells from oxidative damage.

Preparative hydrophobic interaction chromatography purifies cysteine-linked antibody-drug conjugates using aqueous salt gradients.

Cationic polymer nanoparticles deliver siRNA to silence NOX1, reducing reactive oxygen species and treating hepatic fibrosis without systemic toxicity.

Polyglycerol-sulfate graphene derivatives inactivate viruses via ionic interactions, avoiding heparin-induced bleeding complications.

DPOFA fluorenone compound increases renal uric acid excretion to overcome insufficient elimination in gout therapy.

Optimized PEG hydrogel networks overcome structural obstructions to enable controlled, sustained release of larger drug molecules.

Combining PD-1, TGFβ, and PARP inhibitors with radiotherapy to target tumor growth and metastasis.

Crystalline form B of the trifluoroacetate salt resolves TNF-alpha over-secretion safety issues while maintaining high selectivity.

Targeting lipocalin-2 with siRNAs and small molecules reduces invasive breast cancer migration while avoiding chemotherapy limitations.

Merges adsorbed drone brood homogenate and vitamin D3 into one formulation to improve immunity and prevent bone cavities while treating respiratory diseases.

Pre-administering trametinib inhibits Erk1/2 and Smad2 signaling, preventing myofibroblast activation and reducing radiation-induced fibrosis severity.

Inosine and nicotinamide riboside combine to enhance cellular energy reserves through synergistic metabolic pathways.

[6R]-5,10-Methylenetetrahydrofolate boosts 5-fluorouracil activity via stereoisomer-specific therapy, bypassing metabolic activation limits to improve efficacy.

Plasma kallikrein inhibitors block the contact activation pathway, reducing lung inflammation and preventing thrombosis during ECMO therapy.

Alotaketal compounds with specific chirality inhibit viral replication, addressing emerging variants that evade conventional treatments.

Merges dendritic cell immunotherapy with cytokine inhibition to overcome insufficient tumor regression and reduce treatment complexity.

Segmenting covalent and supramolecular crosslinking allows independent tuning of mechanical strength and cell adhesion to inhibit fibrosis.

Pulsed laser radiation heats colorant-loaded nanocapsules in choroidal neovessels, triggering hydrogel phase transitions for targeted drug release.

Targeting acid lipase reduces neutral lipid availability, impairing proliferation in aggressive cancers resistant to standard therapies.

Administering CDC7 inhibitors alongside azacitidine and venetoclax overcomes chemotherapy resistance by inducing apoptosis in proliferative disease cells.

A segmented molecular conjugate recruits E3 ligase to trigger ubiquitin-proteasome degradation of target proteins.

Layered coatings delay methylphenidate release by six to eight hours, maintaining therapeutic levels during daytime while reducing side effects.

Sequential epigenetic treatment inhibits chromatin-modifying enzymes, preventing compensatory pathway activation that causes kinase inhibitor resistance.

Nested particles in a multistage delivery system overcome biological barriers, improving selective targeting and reducing collateral damage.

Micelle-forming surfactants encapsulate lipophilic omega-fatty acids, preventing oxidation and maintaining clarity for extended storage periods.

Replacing high-shear milling with acoustic energy eliminates metal particle shedding and drug degradation while enabling scalable nano-suspension production.

Histidine-lysine polymeric nanoparticles deliver siRNA to inhibit ORF1AB and N-protein genes, reducing viral load in lung tissue.

Acridinedione targets GPR40 to trigger glucose-dependent insulin release, resolving the hypoglycemia risk inherent in traditional antidiabetic treatments.

Selective estrogen receptor modulators enhance alpha-dystroglycan glycosylation to restore muscle function in dystroglycanopathy models.

Supercritical fluid technology dissolves and recrystallizes S-modafinil onto inert supports to form rapid-dissolving granules.

Benzoxazepine derivatives suppress IL-6 and TNF-α release to overcome inadequate proliferation inhibition by current chemotherapeutic agents.

Gene signatures predict survival time in renal cell carcinoma patients, addressing insufficient prognosis accuracy from clinical predictors.

Administering a G(alpha)i2 inhibitor alongside chemotherapeutic drugs prevents chemotherapy-induced cell migration and metastasis in prostate cancer.

Genotyping HLA and KIR alleles selects patients for anti-CD38 antibody therapy, increasing progression-free survival by avoiding resistance.

Surfactant additives in the coating resolve adhesion and uptake contradictions, reducing restenosis risk.

Replacing subjective questionnaires with N-acetyl-L-tryptophan concentration measurements provides objective diagnostic reliability for mood disorders.

Segmenting active-free granules simplifies manufacturing complexity while ensuring consistent alcohol and tamper resistance in the final dosage form.

Polyethylene glycol conjugation extends protein half-life while minimizing non-specific uptake and aggregation in normal tissues.

C8-C16 aliphatic sulfate salts stabilize kinase inhibitor absorption across fed and fasted states, eliminating food effect variability.

Prolinamide derivatives target NaV1.3 channels to resolve the trade-off between treatment efficacy and subtype selectivity in neurological disorders.

AZD4107 inhibits local cortisol to accelerate diabetic wound healing and improve skin resilience.

Covalently grafted oligosaccharide chains on linear polylysine bind bacterial adhesins to block F18+ E. coli attachment, reducing diarrhea in pigs at 8 μg/g.

Polymer conjugates inhibit VCP-mutant Huntingtin protein interaction to prevent neurodegenerative disease progression.

Agomelatine reduces periventricular white matter lesions by up to 59% via dual receptor antagonism, addressing ineffective current therapies.

Amine-modified flavonoids overcome resistance and side effects of conventional therapies by enabling effective oral treatment.

A balloon catheter coating uses a polyethylene glycol-polyvinyl alcohol copolymer binder matrix to stabilize drug distribution.

Low pH self-assembly creates uniform lipid nanoparticles that resolve manufacturing complexity while ensuring efficient airway epithelium delivery.

Chemically modified dsRNA oligonucleotides cross the blood-brain barrier to reduce ApoE levels, addressing delivery constraints for neurodegenerative therapy.

AAV vectors deliver siRNA duplexes to inhibit SOD1 gene expression, reducing protein aggregation and oxidative stress to slow disease progression.

A hard gelatin capsule containing bendamustine and a non-ionic hydrophilic surfactant achieves rapid drug release.

Combining selective dopamine D3 receptor antagonists with opioids reduces tolerance and dependence while maintaining pain relief.

5,6-dihydro-2H-[1,4]oxazin-3-ylamine derivatives inhibit beta-secretase to block neurotoxic peptide generation.

Ice slurry reversibly increases barrier permeability, enabling targeted drug delivery while avoiding systemic toxicity.

Modified TLR4 agonists in liposomes enhance ethanol solubility, reducing reactogenicity and production costs.

Oligonucleotide-functionalized gold nanoparticles enhance cellular uptake and binding affinity for therapeutic delivery.

A stable effervescent tablet composition excludes polyol binders to ensure rapid disintegration and complete solubilization of alendronate in water.

Selective heteroaryl inhibitors block aldosterone synthase, addressing kidney function decline in diabetic nephropathy.

Metabolically stable glycolipid mimetics modulate the TLR4 receptor to resolve target specificity and side effects.

A bacteria-derived lipid composition combines bacterial components with ionizable lipids to boost cellular uptake of heterologous functional agents.

Selective OX1R benzamides resolve the contradiction between treating impulse control deficits and avoiding sleep-inducing side effects.

Formula (I) compound reverses immunosuppression in drug-resistant NTRK tumors.

Aqueous loxoprofen patches incorporate triacetin into the adhesive gel base to dissolve the active ingredient.

Trimethoxybenzyl acetylsinapate activates the Nrf2 pathway to enhance skin antioxidant response.

Combining triazolone HSP90 inhibitors with taxanes overcomes multidrug resistance and reduces toxicity in cancer therapy.

Letrozole crosses the blood-brain barrier to treat primary brain tumors, overcoming obstruction that limits conventional chemotherapy access.

Specific cationic lipid structures optimize transfection efficiency and pharmacological efficacy while reducing cellular toxicity.

4-[(phenylthio)alkyl]-1H-1,2,3-triazole compounds modulate ryanodine receptors to regulate intracellular calcium levels.

SOS2 inhibitors address glaucoma by targeting genetic factors, reducing treatment complexity.

A method formulating vegetable oil blends with balanced omega-6 and omega-3 fatty acids.

Rectal suppository formulations deliver benzodiazepine and NMDA antagonist blends for conscious sedation.

Oral composition delivers astaxanthin and fern extract systemically, eliminating topical irritation while treating sunburn.

Black ginger polyalkoxyflavonoids activate sirtuins tenfold stronger than resveratrol, addressing limited natural availability and weak activation strength.

Composite agents and light exposure reduce jet lag frequency, duration, and intensity by addressing multiple physiological pathways simultaneously.

Introducing polar substituents at the thienopyrimidine R4 position resolves low solubility and metabolic instability in Mnk1/2 inhibitors.

Substituted benzoxazin compounds modulate calcium sensing receptors to lower plasma parathyroid hormone levels in hyperparathyroidism treatment.

Pyrrolopyridinone compounds inhibit BET proteins to control tumor growth while maintaining selectivity against normal cellular functions.

TGFβ inhibitors delay bone marrow failure onset by promoting homologous recombination repair and reducing non-homologous end-joining activity.

Self-assembled hyaluronic acid nanoparticles bind CD44 receptors to reduce body weight and improve glucose metabolism in diabetic models.

Thienoisoquinoline compounds disrupt centrosome integrity to induce mitotic arrest, resolving side effects from traditional chemotherapy.

Matching detected FLT3 and NPM1 mutations to specific inhibitors improves response rates while reducing treatment regimen complexity.

GHG extracted from Kenyan purple tea activates AMPK, reducing fat while avoiding synthetic side effects.

Oxygen linked pyrimidine compounds inhibit specific kinases like JAK2 and FLT3, reducing side effects on healthy cells while treating cancer.

Tricyclic heterocyclic derivatives inhibit ATR kinase to enhance replication inhibitor potency.

Extracting shikonin derivatives from Arnebia decumbens roots addresses the lack of broad-spectrum antibacterial compounds against gram-negative bacteria.

Antibody-based detection identifies low-concentration yeast cell wall components in feed, resolving interference from complex matrices.

Replacing ozone oxidation with borane reduction improves optical purity and scalability of 7H-pyrrolo[2,3-d]pyrimidine synthesis.

Specific crystal lattices improve solubility and stability, addressing manufacturing complexity to treat pulmonary arterial hypertension.

Lyophilized formulations stabilize the compound using citrate buffer and bulking agents to resolve excipient adverse reactions.

Formula I compounds inhibit MCL1 protein to trigger apoptosis, addressing the lack of effective inhibitors for overexpressing cancers.

A feed additive composition containing glucan, silica, mineral clay, and mannan reduces physiological heat stress indicators in animals.